多瑞医药(301075.SZ)发布2024年度业绩，由盈转亏至6266.67万元

智通财经2025-04-17

智通财经APP讯，多瑞医药(301075.SZ)发布2024年年度报告，该公司营业收入为2.41亿元，同比减少28.02%。归属于上市公司股东的净亏损为6266.67万元。归属于上市公司股东的扣除非经常性损益的净亏损为6645.45万元。基本每股亏损为0.79元。2024年度公司业绩大幅下滑，主要受药品价格联动、中药1类新药益肺济生颗粒研发费用增加、部分中间体产品初期生产成本较高以致毛利率为负并...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2528074612?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-17 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2528074612","market":"us","top_or_hot":-1,"title":"多瑞医药(301075.SZ)发布2024年度业绩，由盈转亏至6266.67万元","media":"智通财经","content":"<div>\n<p>智通财经APP讯，多瑞医药(301075.SZ)发布2024年年度报告，该公司营业收入为2.41亿元，同比减少28.02%。归属于上市公司股东的净亏损为6266.67万元。归属于上市公司股东的扣除非经常性损益的净亏损为6645.45万元。基本每股亏损为0.79元。2024年度公司业绩大幅下滑，主要受药品价格联动、中药1类新药益肺济生颗粒研发费用增加、部分中间体产品初期生产成本较高以致毛利率为负并...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1280502.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>多瑞医药(301075.SZ)发布2024年度业绩，由盈转亏至6266.67万元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n多瑞医药(301075.SZ)发布2024年度业绩，由盈转亏至6266.67万元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-17 22:15 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1280502.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，多瑞医药(301075.SZ)发布2024年年度报告，该公司营业收入为2.41亿元，同比减少28.02%。归属于上市公司股东的净亏损为6266.67万元。归属于上市公司股东的扣除非经常性损益的净亏损为6645.45万元。基本每股亏损为0.79元。2024年度公司业绩大幅下滑，主要受药品价格联动、中药1类新药益肺济生颗粒研发费用增加、部分中间体产品初期生产成本较高以致毛利率为负并...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1280502.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"301075","symbol_name":"多瑞医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1280502.html","article_id":"2528074612","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2528074612","pubTimestamp":1744899324,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，多瑞医药(301075.SZ)发布2024年年度报告，该公司营业收入为2.41亿元，同比减少28.02%。归属于上市公司股东的净亏损为6266.67万元。归属于上市公司股东的扣除非经常性损益的净亏损为6645.45万元。基本每股亏损为0.79元。2024年度公司业绩大幅下滑，主要受药品价格联动、中药1类新药益肺济生颗粒研发费用增加、部分中间体产品初期生产成本较高以致毛利率为负并计提存货跌价准备和新收购主体增加固定资产折旧费用等因素影响。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"301075":"多瑞医药","BK0239":"医药制造"},"translate_title":"Duorui Pharmaceuticals (301075. SZ) released its 2024 annual results, turning from profit to loss to 62.6667 million yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"301075":1},"content_text":"智通财经APP讯，多瑞医药(301075.SZ)发布2024年年度报告，该公司营业收入为2.41亿元，同比减少28.02%。归属于上市公司股东的净亏损为6266.67万元。归属于上市公司股东的扣除非经常性损益的净亏损为6645.45万元。基本每股亏损为0.79元。2024年度公司业绩大幅下滑，主要受药品价格联动、中药1类新药益肺济生颗粒研发费用增加、部分中间体产品初期生产成本较高以致毛利率为负并计提存货跌价准备和新收购主体增加固定资产折旧费用等因素影响。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2528074612","isCrawlerRequest":true}